13th week of 2011 patent applcation highlights part 44 |
Patent application number | Title | Published |
20110077220 | 4-OXO,1-4-DIHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. | 2011-03-31 |
20110077221 | Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof - This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle. | 2011-03-31 |
20110077222 | Sustained-Release Opiate and Opiate Derivative Compositions - The present invention provides sustained-release opiate compositions. In particular, the present invention provides sustained-release opiate compositions that include an opiate attached to a blood albumin binder. The present invention also relates to methods of administering an opiate with a sustained release pharmacokinetic profile. | 2011-03-31 |
20110077223 | CHIMERIC PROMOTERS FOR USE IN PLANTS - The present invention provides polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides expression constructs containing the polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides transgenic plants and seeds containing the polynucleotide molecules useful for expressing transgenes in plants. | 2011-03-31 |
20110077224 | LINOLEIC PHOSPHOLIPIDS AND USES THEREOF FOR INHIBITING INFLAMMATORY AND NEURODEGENERATIVE PROCESSES - Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject in need of such treatment. | 2011-03-31 |
20110077225 | 4-Substituted Tetracyclines and Methods of Use Thereof - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression. | 2011-03-31 |
20110077226 | Methods for Inhibiting the Development of Huntington's Disease - This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof. | 2011-03-31 |
20110077227 | NOVEL LUPANE DERIVATIVES - The invention relates to 21-keto triterpene compounds of formula (I): wherein R | 2011-03-31 |
20110077228 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF - The invention relates to 21-keto triterpene compounds of formula (I): | 2011-03-31 |
20110077229 | Steroid Containing Drug Delivery Systems - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 2011-03-31 |
20110077230 | COPPER ORGANOCOMPLEXES, USE THEREOF AS ANTITUMOR MEANS AND FOR PROTECTING HEALTHY TISSUE FROM IONIZING RADIATION - The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from 4-[bis(2-chloroethyl)amino]-D,L-phenyl-alanine (sarcolysine), the hydrochloride thereof, N-(2-furanidil)-5-fluorouracil (tegafur) and aminocarbonylaziridine (leacadin) at acidic to neutral pH in a chloroform/methanol mixture. | 2011-03-31 |
20110077231 | COMPOUNDS - Novel compounds, with the following being exemplary: | 2011-03-31 |
20110077232 | COMPOSITIONS COMPRISING ATORVASTATIN 4-(NITROOXY) BUTYL ESTER AND A HYPOLIPIDEMIC DRUG - The present invention relates to compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic, in particular ezetimibe and fenofibrate. The invention discloses also their use as cholesterol-reducing drugs, as drugs having immunosuppressive properties, antioxidant, antithrombotic and anti-inflammatory activity, effects on endothelial function, and for treating and/or preventing acute coronary syndromes, stroke, atherosclerosis, neurodegenerative disorders, such as Alzheimer's and Parkinson's disease as well as autoimmune diseases, such as multiple sclerosis. | 2011-03-31 |
20110077233 | C-Met Modulators and Method of Use - The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. | 2011-03-31 |
20110077234 | Urea Glucokinase Activators - The invention provides a compound of general formula (I) | 2011-03-31 |
20110077235 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS - The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds. | 2011-03-31 |
20110077236 | NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS - The present invention relates to new substituted carboxylic acid amides of general formula | 2011-03-31 |
20110077237 | KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2011-03-31 |
20110077238 | METHODS AND COMPOSITIONS FOR DETERRING ABUSE - Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10. | 2011-03-31 |
20110077239 | GLYCINE RECEPTOR AGONISTS FOR THE TREATMENT OF PHANTOM PHENOMENA - A medicament for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the production of such a medicament, and a method for the treatment of such phantom phenomena | 2011-03-31 |
20110077240 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY - This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions. | 2011-03-31 |
20110077241 | HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM - The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R | 2011-03-31 |
20110077242 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds and methods for treating diseases mediated by a P2X | 2011-03-31 |
20110077243 | Triazolopyridine Compounds Useful As Kinase Inhibitors - A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase. | 2011-03-31 |
20110077244 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE - The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or a salt thereof. In the formula (1), R | 2011-03-31 |
20110077245 | SUBSTITUTED 2-ALKYL QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) | 2011-03-31 |
20110077246 | BICYCLIC HETEROCYCLIC COMPOUNDS PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THE SAME - The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula | 2011-03-31 |
20110077247 | CLASS OF HISTONE DEACETYLASE INHIBITORS - New histone deacetylase inhibitors according to the general formula (I) | 2011-03-31 |
20110077248 | IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2011-03-31 |
20110077249 | 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES - 1,2,4-Triazolylaminoaryl(heteroaryl)sulfonamide derivatives of formula (I), pharmaceutically acceptable salts thereof, processes for the manufacture of 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives and pharmaceutical compositions containing 1,2,4-triazolylaminoaryl(heteroaryl)sulfonamide derivatives are disclosed: | 2011-03-31 |
20110077250 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR - The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders. | 2011-03-31 |
20110077251 | NOVEL 17 BETA LUPANE DERIVATIVES - The invention relates to 17β lupane derivatives of formula (I): | 2011-03-31 |
20110077252 | PYRIDYL DERIVATIVES, THEIR PREPARATION AND USE - The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1α (HIF-1α) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions caused by deregulation of signaling pathways selected from one or more of PI3K, mTOR and HIF-1α pathways. The pyridyl derivatives are also useful for the treatment of conditions or disorders mediated by TNF-α. | 2011-03-31 |
20110077253 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES - The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders. | 2011-03-31 |
20110077254 | COMPOUNDS - A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, | 2011-03-31 |
20110077255 | SUBSTITUTED XANTHINE DERIVATIVES - This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. | 2011-03-31 |
20110077256 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO - The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from | 2011-03-31 |
20110077257 | SUBSTITUTED DIHYDRO, TRIHYDRO AND TETRAHYDRO CYCLOALKYLOXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF - The present disclosure relates to a series of 2-substituted-di- tri or tetra-hydro-8H-cyclopentaoxazolo[3,2-a]pyrimidin-8-ones and 2-substituted-di-, tetra-, or hexa-hydro-cyclohexaoxazolo[3,2-a]pyrimidin-9-ones of formula (I): | 2011-03-31 |
20110077258 | TREATMENT OF MALARIA - The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same. | 2011-03-31 |
20110077259 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING DERMATOSES - The invention encompasses protectant agents including uracil or a metabolite thereof that effectively prevent and/or treat the cutaneous toxicities and dermatological side-effects associated with chemotherapeutic agents. Additionally, and surprisingly compositions including uracil or a metabolite thereof are effective for treating or preventing various dermatoses. | 2011-03-31 |
20110077260 | METHODS, COMPOSITIONS, AND KITS FOR ORGAN PROTECTION DURING SYSTEMIC ANTICANCER THERAPY - Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents. | 2011-03-31 |
20110077261 | PREVENTION OF HIV-INFECTION - This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals. | 2011-03-31 |
20110077262 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS - The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar | 2011-03-31 |
20110077263 | Methods and Compositions of Toll-Like Receptor (TLR) Agonists - There is provided a method of activating a Langerhans cell (LC) exposed to a human papillomavirus (HPV) to induce a HPV-specific immune response, by administering to a subject an effective amount of a toll-like receptor (TLR) agonist, thereby activating the LC exposed to the HPV to induce the HPV-specific immune response. | 2011-03-31 |
20110077264 | DERIVATIVES OF 5-PYRIDINYL-1-AZABICYCLO[3.2.1]OCTANE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The invention relates to compounds having general formula (I), wherein R is as defined herein. | 2011-03-31 |
20110077265 | INHIBITORS OF IAP - The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein. | 2011-03-31 |
20110077266 | Diamine Derivatives - The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism. | 2011-03-31 |
20110077267 | TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT - The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: | 2011-03-31 |
20110077268 | KINASE INHIBITORS AND METHODS OF USE - The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PB kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications. | 2011-03-31 |
20110077269 | DERIVATIVES FOR MODULATION OF ION CHANNELS - Sulfonamide derivatives act as ion channel antagonists. The compositions are useful for treating or relieving pain-related conditions. | 2011-03-31 |
20110077270 | Compositions and Methods for Treating Ocular Inflammation with Lower Risk of Increased Intraocular Pressure - A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application, injection, or implantation in an affected eye to treat or control the ocular inflammatory disease or condition. | 2011-03-31 |
20110077271 | Process for the Preparation of Donepezil Hydrochloride - The present invention provides a process for preparing donepezil or a salt thereof, the process comprising reducing a 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methylene]pyridonium halide of formula II, wherein X is bromide or chloride, in the presence of an ionic compound, a solvent, a catalyst and a source of hydrogen, to form donepezil and optionally converting the donepezil to the salt thereof. | 2011-03-31 |
20110077272 | PULMONARY FORMULATIONS OF TRIPTANS - A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route. | 2011-03-31 |
20110077273 | NEW BENZIMIDAZOLE DERIVATIVES - The present invention relates to compounds of formula (I), | 2011-03-31 |
20110077274 | SUBSTITUTED-ARYL-2-PHENYLETHYL-1H-IMIDAZOLE COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS - A compound having selective modulating activity at the alpha 2B and/or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: | 2011-03-31 |
20110077275 | ANTIOXIDANT COMPOSITIONS FOR SOFT ORAL TISSUE AND METHODS OF FORMULATION AND USE THEREOF - One embodiment of the invention is directed to an oral antioxidant composition including between 0.0001% and 5.0% w/w antioxidant, wherein the antioxidant includes cinnamic acid derivative, tetrahydrocurcuminoids, or phloretin and an orally pharmaceutically acceptable carrier. The composition may have a pH of at least 5.0. According to still further embodiments, the composition may also include between 0.0001% and 5.0% w/w of one or two more additional antioxidants that include cinnamic acid derivative, tetrahydrcurcuminoids, phloretin, or a stilbene derivative. In more particular embodiments, the cinnamic acid derivative may include trans-ferulic acid, the tetrahydrocurcuminoids may include tetrahydrcurcuminoids CG™, or the stilbene derivative may include resveratrol. Other embodiments may relate to methods of treating or preventing an oral disease by applying topically an antioxidant composition as described above. | 2011-03-31 |
20110077276 | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments - The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a side effect associated with dopaminergic agent treatment. | 2011-03-31 |
20110077277 | ORGANIC COMPOUNDS - The present invention provides compounds of the following structure; | 2011-03-31 |
20110077278 | Antifungal compositions and methods - A combination product including a mixture of 3-iodpropynyl-N-n-butylcarbamate (“IPBC”) and 2-n-N-butyl-1,2-benzisothiazolin-3-one (“BBIT) for use as a fungicide and growth inhibitor in industrial applications. Combination products of the present invention are effective for inhibiting the growth of microorganisms, and exhibit a synergistic antifungal effect against fungi such as, for example, | 2011-03-31 |
20110077279 | ANGIOTENSIN II RECEPTOR ANTAGONISTS - A compound having the structure | 2011-03-31 |
20110077280 | Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds. | 2011-03-31 |
20110077281 | Formulations Comprising Triptain Compounds - The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T | 2011-03-31 |
20110077282 | NOVEL COMPOUNDS FROM ANTRODIA CAMPHORATA - Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of | 2011-03-31 |
20110077283 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES - The present invention relates to methods and assays for identifying agents capable of inhibiting the mutant huntingtin protein, inhibiting or reducing polyglutamine-induced protein aggregation, and/or altering huntingtin protein conformation, which inhibition is useful in the prevention, amelioration and/or treatment of neurodegenerative diseases, and protein aggregation diseases more generally. In particular, the present invention provides methods and assays for identifying agents for use in the prevention and/or treatment of Huntington's disease. The invention provides polypeptide and nucleic acid TARGETs and siRNA sequences based on these | 2011-03-31 |
20110077284 | DRY POWDER COMPOSITIONS FOR RNA INFLUENZA THERAPEUTICS - A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of a dry powder formulation. | 2011-03-31 |
20110077285 | RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PIK3CA EXPRESSION - The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods for modulating the expression of PIK3CA using the oligomers, including methods of treatment. | 2011-03-31 |
20110077286 | OLIGONUCLEOTIDE DUPLEXES COMPRISING DNA-LIKE AND RNA-LIKE NUCLEOTIDES AND USES THEREOF - Novel oligonucleotide pairs which can form a duplex comprising one or more DNA-like nucleotides (e.g., 2′-substituted arabinonucleotides (ANA)); in combination with one or more RNA-like nucleotides (e.g., 2′-substituted ribonucleotides (RNA) and/or locked nucleic acid nucleotides (LNA)), are disclosed. The use of such oligonucleotide duplexes, such as for silencing the expression of a nucleic acid or gene of interest using small interfering RNA (siRNA) technologies, is also disclosed. | 2011-03-31 |
20110077287 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED MRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration. In addition a process is described for determining sequence modifications that serve for the stabilisation and translation optimisation of mRNA. | 2011-03-31 |
20110077288 | Pharmaceutical Compositions for Treatment of MicroRNA Related Diseases - The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval. | 2011-03-31 |
20110077289 | METHOD OF TREATING PNEUMOCONIOSIS WITH OLIGODEOXYNUCLEOTIDES - Methods are disclosed for treating, preventing or reducing the risk of developing occupational lung diseases, such as pneumoconiosis. In several embodiments, the methods include administering a therapeutically effective amount of the suppressive ODN to a subject having or at risk of developing a pneumoconiosis, thereby treating or inhibiting the pneumoconiosis. In several examples, thee subject can have or be at risk of developing silicosis, asbestosis or berryliosis. The method can include selecting a subject exposed to, or at risk of exposure to, inorganic particles, including, but not limited to silica, asbestos, berrylium, coal dust, or bauxite. | 2011-03-31 |
20110077290 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS - A compound represented by the formula (1): | 2011-03-31 |
20110077291 | Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof - The present invention relates to the field of medical technology. More specifically, the present invention relates to a preparation of taxanes for intravenous administration, which consists of two parts: a drug solution and an emulsion. Said drug solution consists of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein said solvent for injection is an organic solvent. Said emulsion includes a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When used, the drug solution at the clinical dosage can be added and mixed homogeneously in the emulsion to perform intravenous drip directly; or the drug solution at the clinical dosage can also be firstly added into the emulsion with no less than 5 times volume of the drug solution and then a predetermined amount of normal saline or glucose solution for injection is added to perform intravenous drip. The preparation of the present invention does not contain solubilizer and has advantages of little toxicity, safety, effectiveness, stability and economy. The fat emulsion is also used as a nutritional replenishment, thus achieving a better therapeutic effect. In addition, the normal saline or glucose solution for injection can be used to replace a considerable amount of the emulsion, which makes the preparation, therefore, not only cost-efficient, but also convenient for transportation and storage in practice. | 2011-03-31 |
20110077292 | FORSKOLIN CARBONATES AND USES THEREOF - The present invention provides methods for reducing body weight. In particular, the present invention provides methods for reducing body weight by administering a composition comprising a forskolin 1α,9α-carbonate compound of the formula: | 2011-03-31 |
20110077293 | GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 2011-03-31 |
20110077294 | R-(-) / S-(+)-7-[3-N SUBSTITUTED AMINO-2 HYDROXYPROPOXY] FLAVONES - The present invention provides an optically active compound of general formula (I) and salts thereof: wherein R′ is selected from a group consisting of t-butyl amine, n-butylamine, iso-butylamine, iso-propyl amine, 4-phenyl-piperazine-1-ylamine, 4-(2-methoxyphenyl)-piperazin-1-ylamine, and 3,4-dimethoxy phenethyl amine; wherein R | 2011-03-31 |
20110077295 | ANDROGRAPHOLIDE DERIVATIVES AND USE THEREOF IN MANUFACTURE OF MEDICAMENTS - The present invention relates to an andrographolide derivative of the formula (I), wherein R | 2011-03-31 |
20110077296 | METHOD AND COMPOSITION FOR DELIVERING ZINC TO THE NASAL MEMBRANE - A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body. | 2011-03-31 |
20110077297 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION AND HYPERKERATOTIC LESIONS - A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound (NVX-207), a related compound, or a pharmaceutically acceptable salt thereof to the mammal. | 2011-03-31 |
20110077298 | Retinoid Derivative and Pharmaceutical Composition and Use Thereof - The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and skin disorders, such as psoriasis and acne. | 2011-03-31 |
20110077299 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION - The present invention relates to a phenylalanine derivative of Formula (I) wherein X | 2011-03-31 |
20110077300 | Metabolic Benefits to Butyrate as a Chronic Diet Supplement - Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin tolerance were all reserved in the butyrate-treated mice. The body fat content was maintained at 10% without a reduction in food intake. Adaptive thermogenesis and fatty acid oxidation were enhanced. An increase in mitochondria function and biogenesis was observed in the skeletal muscle and brown fat, and Type 1 muscle fiber was enriched in the skeletal muscle. In genetically obese mice, supplementation of butyrate led to an increase in insulin sensitivity and reduction in adiposity. Dietary supplementation of butyrate can prevent and treat diet-induced insulin resistance. | 2011-03-31 |
20110077301 | NOVEL METHODS OF ADMINISTERING A MIXTURE OF FATTY ACIDS FOR THE TREATMENT OF NON-HUMAN MAMMALS - Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration. | 2011-03-31 |
20110077302 | ENZYMATIC SYNTHESIS OF SPHINGOLIPIDS - The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphingolipids or compositions. | 2011-03-31 |
20110077303 | INCREASING GLUTATHIONE LEVELS FOR THERAPY - The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels. | 2011-03-31 |
20110077304 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS. - The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 2011-03-31 |
20110077305 | 5-LIPOXYGENASE INHIBITORS - The use of compounds of the formula (I) Ar | 2011-03-31 |
20110077306 | STAT3 INHIBITING COMPOSITIONS AND METHODS - STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of STAT3 activity is shown to reduce intraocular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents STAT3 from transcriptionally activating downstream gene targets that are known to be associated with retinal inflammation and neovascularization and such disorders as age-related macular degeneration. | 2011-03-31 |
20110077307 | ASTAXANTHIN-CONTAINING PET FOODS - There is provided pet food comprising astaxanthin and/or an ester thereof as an active component and having an effect of deodorizing excrement such as urine and feces, effects of improving sleep, sensibility such as perception and cognition, and visual sense, and an effect of treating, improving or preventing diabetes and diabetic complications. The pet food can deodorize excrement such as urine and feces, improve sleep, sensibility such as perception and cognition, and visual sense, and treat, improve or prevent diabetes and diabetic complications. | 2011-03-31 |
20110077308 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the human bitter-taste receptor hTAS2R40 and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R40 bitter taste transduction or bitter taste response. | 2011-03-31 |
20110077309 | HUMECTANT COMPOSITION - The present invention relates to a humectant composition containing, as component (A), at least one member selected from a menthol derivative represented by the following formula (1) and p-menthane-3,8-diol: | 2011-03-31 |
20110077310 | HYDROPHILIC POLYURETHANE COATINGS - The present invention relates to the use of specific polyurethane coatings, wherein the polyurethane urea is terminated by a copolymer unit of polyethylene oxide and polypropylene oxide. | 2011-03-31 |
20110077311 | METHOD FOR HANDLING VISCOUS LIQUID CRUDE HYDROCARBONS - A method for handling viscous liquid crude hydrocarbons is disclosed. The method involves (a) obtaining an emulsion comprising an aqueous fraction and a liquid crude hydrocarbon fraction, wherein the liquid crude hydrocarbon fraction has a first viscosity and contains an oil-soluble compound that reversibly converts to a surfactant under basic conditions, and further wherein the emulsion has a second viscosity that is less than the first viscosity of the liquid crude hydrocarbon fraction; and (b) breaking the emulsion by contacting the emulsion with a carbon dioxide-containing material to convert at least a portion of the surfactant to the oil-soluble compound. | 2011-03-31 |
20110077312 | METHOD TO IMPROVE THE SELECTIVITY OF POLYBENZOXAZOLE MEMBRANES - The present invention discloses a novel method to improve the selectivities of polybenzoxazole (PBO) membranes prepared from aromatic polyimide membranes for gas, vapor, and liquid separations. The PBO membranes that were prepared by thermal treating aromatic polyimide membranes containing between 0.05 and 20 wt-% of a poly(styrene sulfonic acid) polymer. These polymers showed up to 95% improvement in selectivity for CO | 2011-03-31 |
20110077313 | FOAMABLE RESIN COMPOSITION AND FOAMED BODY - A foamable resin composition according to the present invention comprises 10 parts by weight or less, preferably 0.5 to 8 parts by weight of a biodegradable resin and/or polyolefin resin, 10 to 30 parts by weight of water and 0.01 to 5 parts by weight of an inorganic filler, with respect to 100 parts by weight of a modified starch. The modified starch is preferably at least one of oxidized starches, esterified starches, acetylated starches and cationic starches. The foamable resin composition can maintain strength, etc., of the foamed body obtained at a practical level even though the amount of the biodegradable resin and/or polyolefin resin is reduced as much as possible, and has a cost advantage. | 2011-03-31 |
20110077314 | 1,3- OR 1,4-BIS(AMINOMETHYL)CYCLOHEXANE-INITIATED POLYOLS AND RIGID POLYURETHANE FOAM MADE THEREFROM - Polyether polyols are initiated with 1,3- or 1,4-bis(aminomethyl)cyclohexanes. The polyols are useful in making rigid polyurethane foams, especially foams for pour-in-place applications, where they give a good combination of low k-factor and short demold times. | 2011-03-31 |
20110077315 | METHYLENE BIS(CYCLOHEXYLAMINE)-INITIATED POLYOLS AND RIGID POLYURETHANE FOAM MADE THEREFROM - Polyether polyols are initiated with methylene bis(cyclohexylamines). The polyols are useful in making rigid polyurethane foams, especially foams for pour-in-place applications, where they give a good combination of low k-factor and short demold times. | 2011-03-31 |
20110077316 | Biosealant Protective Barrier for Surfaces - A protective barrier sealant product and methods of applying the same, including a high density polyurethane material provided in an amount, volume, and density effective for providing a protective barrier for a surface, wherein the polyurethane material is combined with at least one active agent just prior to or at the time of application of the sealant product to an object surface. | 2011-03-31 |
20110077317 | Polyolefin-Based Crosslinked Articles - Methods for making a crosslinked elastomeric composition and articles made of the same are provided. In at least one specific embodiment, an elastomeric composition comprising at least one propylene-based polymer is blended with at least one component selected from the group consisting of multifunctional acrylates, multifunctional methacrylates, functionalized polybutadiene resins, functionalized cyanurate, and allyl isocyanurate; and blended with at least one component selected from the group consisting of hindered phenols, phosphites, and hindered amines. The propylene-based polymer can include propylene derived units and one or more dienes, and have a triad tacticity of from 50% to 99% and a heat of fusion of less than 80 J/g. The blended composition can then be extruded and crosslinked. The extruded polymer can be crosslinked using electron beam radiation having an e-beam dose of about 100 KGy or less. The crosslinked polymers are particularly useful for making fibers and films. | 2011-03-31 |
20110077318 | RESIN COMPOSITION FOR PRODUCING OPTICAL COMPONENT AND USE THEREOF - The present invention provides a resin composition for producing an optical component in which resin composition respective of a (meth)acrylic equivalent and a content of a repeating unit represented by the general formula (1) are adjusted to given ranges, an optical component which is made of the resin composition, and an image display device. The resin composition of the present invention for producing an optical component is arranged such that the resin composition contains at least one kind of compound whose molecule contains the repeating unit represented by the general formula (1) and at least one (meth)acryloyl group and the (meth)acrylic equivalent and the content of the repeating unit meet the given ranges. | 2011-03-31 |
20110077319 | PIGMENT DISPERSION AND INK COMPOSITION USING THE SAME - A pigment dispersion including a pigment and a block polymer including a repeating unit including a hetero ring residue or an anthraquinone ring residue of a colorant is disclosed. | 2011-03-31 |